Reference
Fitzpatrick, Anne M, et al. “Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation”. J. Allergy Clin. Immunol. Pract., vol. 7, no. 3, Mar. 2019, pp. 915–924.e7.
Abstract
BACKGROUND: Recurrent preschool wheezing is a heterogeneous
disorder with significant morbidity, yet little is known about
phenotypic determinants and their impact on clinical outcomes.
OBJECTIVE: Latent class analysis (LCA) was used to identify
latent classes of recurrent preschool wheeze and their
association with future exacerbations and inhaled corticosteroid
(ICS) treatment response. METHODS: Data from 5 clinical trials
of 1708 children aged 12 to 71 months with recurrent wheezing
were merged. LCA was performed on 10 demographic, exposure, and
sensitization variables to determine the optimal number of
latent classes. The primary outcome was the annualized rate of
wheezing exacerbations requiring systemic corticosteroids during
the study intervention period; the secondary outcome was the
time to first exacerbation. Exploratory analyses examined the
effect of daily ICS treatment on exacerbation outcomes. RESULTS:
Four latent classes of recurrent wheezing were identified; these
were not distinguished by current symptoms or historical
exacerbations but differed with regard to allergen sensitization
and/or exposures. Annualized exacerbation rates (mean $\pm$
SEM/year) were 0.65 $\pm$ 0.06 for class 1 (``minimal
sensitization''), 0.93 $\pm$ 0.10 for class 2 (``sensitization
with indoor pet exposure''), 0.60 $\pm$ 0.07 for class 3
(``sensitization with tobacco smoke exposure''), and 0.81 $\pm$
0.10 for class 4 (``multiple sensitization and eczema'') (P <
.001). In a research setting of high adherence, daily ICS
treatment improved exacerbation rates in classes 2 and 4 but not
the other groups. CONCLUSIONS: Sensitization and exposure
assessments are useful in the prediction of future exacerbation
and may identify children most likely to respond favorably to
daily ICS treatment.